Tolerance Bio, Inc., a company based in Philadelphia, USA, has acquired specific thymus-related indications for Hyleukin-7 (efineptakin alfa, NT-I7) from NeoImmuneTech, Inc. (950220). Instead of independently developing and conducting a Phase 1 trial for its own candidate, the company is preparing for a Phase 2 trial using an asset with existing human administration data. NeoImmuneTech will receive 4% equity in Tolerance Bio on a fully diluted basis, along with potential milestone payments of up to USD 260 million and royalties based on net sales, in lieu of an upfront cash payment. Tolerance Bio's USD 17.2 million seed funding, secured in October 2024, also supports this clinical-focused strategy.

NT-I7 targets T-cell generation through IL-7 receptor signaling. NT-I7 is a fusion protein consisting of a recombinant human interleukin-7 (IL-7) and a modified Fc region (hyFc). It targets the IL-7 receptor signaling pathway, which is formed by the IL-7 receptor alpha (CD127) and the common gamma chain. This pathway regulates T-cell differentiation in the thymus and the survival of peripheral CD4 and CD8 T-cells, aligning with Tolerance Bio's platform aimed at reconstituting the immune system, which may be weakened by aging or disease. NT-I7 has been administered in clinical trials for Kaposi's sarcoma (NCT04893018) and in a Phase 1b/2a trial for solid tumors. The product is in the development stage and has not undergone FDA, EMA, or PMDA approval or advisory committee review. Therefore, the key value inflection point for this deal hinges on whether existing safety data can translate into effective CD4 T-cell reconstitution in HIV immunological non-responders.

The planned Phase 2 trial will target HIV immunological non-responders (INR). INR are HIV-infected individuals who, despite viral suppression with antiretroviral therapy (ART), do not achieve sufficient CD4 T-cell recovery. Literature suggests that approximately 8-42% of long-term ART patients fall into this category, and they are at increased risk of opportunistic infections, as well as non-AIDS-related events such as cancer and cardiovascular disease. Current standard treatment involves ART regimens like Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) to suppress viral replication, but there are no approved therapies that directly restore thymus function and immune reconstitution. Jecho Biopharmaceuticals, a Chinese company, is also conducting a Phase 1/2 trial (NCT07443228) with its recombinant IL-7, JL18008, targeting HIV INR, initiating a competitive landscape with a similar mechanism of action.

The commercial success of NT-I7 will depend more on its differentiated position as an adjunctive therapy rather than on the large HIV market. The global HIV therapeutics market is projected to reach USD 38.27 billion in 2025, with Gilead Sciences (GILD) generating USD 19.6 billion in HIV revenue in 2024. However, NT-I7 is not intended to replace viral suppressive agents but rather to address the residual immune deficiency after ART. Therefore, the actual target market should be narrowed to the INR patient population. In the thymus regeneration competition, United Therapeutics Corporation (UTHR) acquired Thymmune Therapeutics in July 2026 for USD 140 million in cash and up to USD 160 million in contingent payments, with Thymmune developing a preclinical iPSC-derived thymic cell therapy (THY-100). NT-I7 is a protein therapeutic that is simpler to manufacture, distribute, and administer repeatedly compared to cell therapies. However, it must demonstrate the magnitude and duration of CD4 T-cell recovery, as well as reductions in infections and non-AIDS events, in the Phase 2 trial for its convenience to translate into a commercial advantage.